The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Surufatinib combine immune checkpoint inhibitorDrug: AG/FOLFIRINOX
- Registration Number
- NCT06378580
- Lead Sponsor
- Luo Cong
- Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC (mPDAC). Surufatinib is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGFR) 1, 2, 3, fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor (CSF-1R), and ex vivo experiments have demonstrated its effect on PC models.
A retrospective analysis of patients with PDAC who underwent surufatinib at Zhejiang Cancer Hospital (Hangzhou,China) from July 2022 to July 2023.The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing surufatinib in the investigators' hospital.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
(i) were over 18 years old; (ii) had a histological diagnosis of pancreatic adenocarcinoma; (iii) had at least one measurable lesion; (iv) had undergone at least two cycles of surufatinib treatment.
(i)non-R0 resection; (ii) Combined with other malignant tumors.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Surufatinib combine immune checkpoint inhibitor Surufatinib combine immune checkpoint inhibitor - Chemotherapy AG/FOLFIRINOX -
- Primary Outcome Measures
Name Time Method Median progression-free survival 5 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zhejiang Province Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China